Rivaroxaban-loaded SLNs with treatment potential of deep vein thrombosis: in-vitro, in-vivo, and toxicity evaluation
暂无分享,去创建一个
A. Zeb | F. Din | Muhammad Imran | S. Sarwar | Kalim Ullah | Xuemei Luo | Aiman Saleem | Uswa Shafique
[1] Han‐Gon Choi,et al. A detailed insight of the tumor targeting using nanocarrier drug delivery system , 2023, Drug delivery.
[2] F. Din,et al. Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of Cutaneous leishmaniasis , 2023, Drug delivery.
[3] Han‐Gon Choi,et al. Mannosylated imiquimod-terbinafine co-loaded transethosomes for cutaneous leishmaniasis; assessment of its anti-leishmanial potential, in vivo safety and immune response modulation. , 2022, Biomaterials advances.
[4] Han‐Gon Choi,et al. Levosulpiride-loaded nanostructured lipid carriers for brain delivery with antipsychotic and antidepressant effects. , 2022, Life sciences.
[5] F. Din,et al. Statistical optimization of co-loaded rifampicin and pentamidine polymeric nanoparticles for the treatment of cutaneous leishmaniasis , 2022, Journal of Drug Delivery Science and Technology.
[6] Han‐Gon Choi,et al. Hydroxypropyl-β-cyclodextrin-based solid dispersed granules: A prospective alternative to conventional solid dispersion. , 2022, International journal of pharmaceutics.
[7] A. Zeb,et al. Statistically designed dexibuprofen loaded solid lipid nanoparticles for enhanced oral bioavailability , 2022, Journal of Drug Delivery Science and Technology.
[8] Salman Khan,et al. Macrophage targeting of nitazoxanide-loaded transethosomal gel in cutaneous leishmaniasis , 2022, Royal Society Open Science.
[9] Salman Khan,et al. Antileishmanial Agents Co-loaded in Transfersomes with Enhanced Macrophage Uptake and Reduced Toxicity , 2022, AAPS PharmSciTech.
[10] Han‐Gon Choi,et al. Cilostazol-loaded solid lipid nanoparticles: Bioavailability and safety evaluation in an animal model , 2022, Journal of Drug Delivery Science and Technology.
[11] R. Ruiz-Soto,et al. Effect of hepatic impairment on the pharmacokinetics of ripretinib. , 2022, Journal of Clinical Oncology.
[12] Han‐Gon Choi,et al. New potential application of hydroxypropyl-β-cyclodextrin in solid self-nanoemulsifying drug delivery system and solid dispersion. , 2021, Carbohydrate polymers.
[13] A. Yousaf,et al. Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery , 2021, BioMed research international.
[14] Guimin Zhang,et al. Synthesis, Characterization, and Properties of Rivaroxaban New Crystalline Forms , 2021, Crystal Research and Technology.
[15] V. Patravale,et al. Solid lipid nanoparticles for hydrophilic drugs. , 2021, Journal of controlled release : official journal of the Controlled Release Society.
[16] F. Din,et al. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight , 2021, Journal of Nanobiotechnology.
[17] Syeda Sohaila Naz,et al. Macrophage targeting with the novel carbopol-based miltefosine-loaded transfersomal gel for the treatment of cutaneous leishmaniasis: in vitro and in vivo analyses , 2021, Drug development and industrial pharmacy.
[18] Han‐Gon Choi,et al. Particle and Gel Characterization of Irinotecan-Loaded Double-Reverse Thermosensitive Hydrogel , 2021, Polymers.
[19] Han‐Gon Choi,et al. Improved Bioavailability and High Photostability of Methotrexate by Spray-Dried Surface-Attached Solid Dispersion with an Aqueous Medium , 2021, Pharmaceutics.
[20] A. Zaky,et al. Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: in vitro and in vivo evaluation , 2020, Pharmaceutical development and technology.
[21] P. Sathler,et al. Novel rivaroxaban—loaded poly(lactic-co-glycolic acid)/poloxamer nanoparticles: preparation, physicochemical characterization, in vitro evaluation of time-dependent anticoagulant activity and toxicological profile , 2020, Nanotechnology.
[22] Jeong-Sook Park,et al. Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals , 2020, Pharmaceutics.
[23] Han‐Gon Choi,et al. Preparation, in-vitro and in-vivo evaluation of Rifampicin and Vancomycin Co-loaded transfersomal gel for the treatment of cutaneous leishmaniasis , 2020 .
[24] Mujeeb-ur-Rehman,et al. Development, In vitro and In vivo Evaluation of Miltefosine Loaded Nanostructured Lipid Carriers for the Treatment of Cutaneous Leishmaniasis. , 2020, International journal of pharmaceutics.
[25] H. Björnsson,et al. Liver injury caused by oral anticoagulants: A population‐based retrospective cohort study , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[26] Zikai Song,et al. Current status of rivaroxaban in elderly patients with pulmonary embolism (Review) , 2020, Experimental and therapeutic medicine.
[27] Hong-wei Zhang,et al. Pathogenesis and management of heparin-induced thrombocytopenia and thrombosis. , 2020, Clinica chimica acta; international journal of clinical chemistry.
[28] A. Zeb,et al. Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity. , 2020, International journal of pharmaceutics.
[29] J. Weitz,et al. Novel Antithrombotic Strategies for Treatment of Venous Thromboembolism. , 2020, Blood.
[30] F. Din,et al. Development of levosulpiride-loaded solid lipid nanoparticles and their in vitro and in vivo comparison with commercial product , 2020, Journal of microencapsulation.
[31] F. Din,et al. Rifampicin-loaded nanotransferosomal gel for treatment of cutaneous leishmaniasis: passive targeting via topical route. , 2020, Nanomedicine.
[32] Dhanunjaya R. Lakkireddy,et al. Direct oral anticoagulants: a review on the current role and scope of reversal agents , 2019, Journal of Thrombosis and Thrombolysis.
[33] Dongqing Wei,et al. An unexpected dynamic binding mode between coagulation factor X and Rivaroxaban reveals importance of flexibility in drug binding , 2019, Chemical biology & drug design.
[34] Sosipatros Bratsos,et al. Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects , 2019, Cureus.
[35] Zia-ur-Rehman,et al. Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product , 2019, Journal of Drug Delivery Science and Technology.
[36] Han‐Gon Choi,et al. Revaprazan-loaded surface-modified solid dispersion: physicochemical characterization and in vivo evaluation , 2019, Pharmaceutical development and technology.
[37] A. Zeb,et al. Simvastatin‐loaded solid lipid nanoparticles for enhanced anti‐hyperlipidemic activity in hyperlipidemia animal model , 2019, International journal of pharmaceutics.
[38] A. Cohen,et al. Rivaroxaban and the EINSTEIN clinical trial programme , 2019, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[39] Francesca N. Delling,et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.
[40] G. Sulaiman,et al. Fabrication of hesperidin nanoparticles loaded by poly lactic co-Glycolic acid for improved therapeutic efficiency and cytotoxicity , 2019, Artificial cells, nanomedicine, and biotechnology.
[41] A. Zeb,et al. Potential of nanoparticulate carriers for improved drug delivery via skin , 2018, Journal of Pharmaceutical Investigation.
[42] A. Corsini,et al. Pharmacokinetic drug interactions of the non‐vitamin K antagonist oral anticoagulants (NOACs) , 2018, Pharmacological research.
[43] P. Sathler,et al. Synthesis and evaluation of the cytotoxic activity of Furanaphthoquinones tethered to 1H-1,2,3-triazoles in Caco-2, Calu-3, MDA-MB231 cells. , 2018, European journal of medicinal chemistry.
[44] Han‐Gon Choi,et al. Novel revaprazan-loaded gelatin microsphere with enhanced drug solubility and oral bioavailability , 2018, Journal of microencapsulation.
[45] Sanjaya K. Samal,et al. Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion. , 2018, Molecular pharmaceutics.
[46] F. Din,et al. Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell , 2018, Drug delivery.
[47] N. Huda,et al. Advanced colloidal technologies for the enhanced bioavailability of drugs , 2018 .
[48] A. Zeb,et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors , 2017, International journal of nanomedicine.
[49] G. Khan,et al. Nanotechnology: from In Vivo Imaging System to Controlled Drug Delivery , 2017, Nanoscale Research Letters.
[50] Bai-Wang Sun,et al. Compatibility study of rivaroxaban and its pharmaceutical excipients , 2017, Journal of Thermal Analysis and Calorimetry.
[51] Y. Oh,et al. Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration. , 2017, Acta biomaterialia.
[52] S. Ku,et al. Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration , 2017, Drug delivery.
[53] H. Hamishehkar,et al. The Impact of Variables on Particle Size of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers; A Comparative Literature Review. , 2016, Advanced pharmaceutical bulletin.
[54] R. Linhardt,et al. Heparin and anticoagulation. , 2016, Frontiers in bioscience.
[55] Han‐Gon Choi,et al. Novel piroxicam-loaded nanospheres generated by the electrospraying technique: physicochemical characterisation and oral bioavailability evaluation , 2016, Journal of microencapsulation.
[56] G. Breithardt,et al. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF , 2015, Circulation.
[57] K. Adibkia,et al. Box-Behnken experimental design for preparation and optimization of ciprofloxacin hydrochloride-loaded CaCO3 nanoparticles , 2015 .
[58] Y. Oh,et al. Comparative study on solid self-nanoemulsifying drug delivery and solid dispersion system for enhanced solubility and bioavailability of ezetimibe , 2015, International journal of nanomedicine.
[59] M. Santos-Silva,et al. Nanoparticles Made From Xyloglucan-Block-Polycaprolactone Copolymers: Safety Assessment for Drug Delivery. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[60] Y. Oh,et al. Development of a novel solid lipid nanoparticles-loaded dual-reverse thermosensitive nanomicelle for intramuscular administration with sustained release and reduced toxicity , 2015 .
[61] Han‐Gon Choi,et al. Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability , 2015, Archives of pharmacal research.
[62] Rui Li,et al. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box–Behnken design , 2014, Journal of liposome research.
[63] M. Khoshayand,et al. Docetaxel Loaded PEG-PLGA Nanoparticles: Optimized Drug Loading, In-vitro Cytotoxicity and In-vivo Antitumor Effect , 2014, Iranian journal of pharmaceutical research : IJPR.
[64] Han‐Gon Choi,et al. Flurbiprofen-loaded nanoparticles prepared with polyvinylpyrrolidone using Shirasu porous glass membranes and a spray-drying technique: nano-sized formation and improved bioavailability , 2013, Journal of microencapsulation.
[65] A. Halabi,et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. , 2013, British journal of clinical pharmacology.
[66] Karsten Mäder,et al. Solid lipid nanoparticles , 2012 .
[67] U. Schubert,et al. Poly(2-ethyl-2-oxazoline) as alternative for the stealth polymer poly(ethylene glycol): comparison of in vitro cytotoxicity and hemocompatibility. , 2012, Macromolecular bioscience.
[68] R. Müller,et al. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. , 2011, International journal of pharmaceutics.
[69] H. Bruck,et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. , 2010, British journal of clinical pharmacology.
[70] Marilena Loizidou,et al. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.
[71] G. Abdelbary,et al. Diazepam-Loaded Solid Lipid Nanoparticles: Design and Characterization , 2009, AAPS PharmSciTech.
[72] G. Yener,et al. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives , 2007, International journal of nanomedicine.
[73] R. Murthy,et al. Etoposide-loaded nanoparticles made from glyceride lipids: Formulation, characterization, in vitro drug release, and stability evaluation , 2005, AAPS PharmSciTech.
[74] M. Petró‐Turza,et al. The International Organization for Standardization. , 2003 .
[75] Thomas Kissel,et al. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. , 2003, Biomaterials.
[76] M. Sznitowska,et al. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. , 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[77] K. Mäder,et al. Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.
[78] R. Müller,et al. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[79] M. Eichelbaum. Pharmacokinetic Drug Interactions , 1986, Journal of clinical pharmacology.
[80] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[81] A. Blenkinsop,et al. World Health , 1957, Nature.
[82] C. Dolea,et al. World Health Organization , 1949, International Organization.
[83] P. Patel. Formulation, development and evaluation of rivaroxaban tablets by using solubility enhancement technique , 2017 .
[84] N. Kleiman,et al. Novel Antithrombotic Strategies , 1998 .
[85] E. Lecocq. Development in vitro and in vivo of a Mixture of Variants of Myco. tuberculosis, Sensitive and Resistant to Isoniazid. , 1953 .